Where does Inmatics Biotechnologies GMBH rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Inmatics Biotechnologies GMBH ranks #40,914 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Inmatics Biotechnologies GMBH hold?

Inmatics Biotechnologies GMBH holds 6 US utility patents granted between 2018 and 2020, spanning 8 technology areas.

What is Inmatics Biotechnologies GMBH's Innovation Score?

Inmatics Biotechnologies GMBH has an Innovation Score of 28.6 out of 100 (28th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Inmatics Biotechnologies GMBH focus on?

Inmatics Biotechnologies GMBH's top technology area is C07K (Peptides) with 6 patents, ranking #1,362 of 3,615 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Inmatics Biotechnologies GMBH's patent grant rate increasing or decreasing?

Inmatics Biotechnologies GMBH's recent grant velocity is -50% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Inmatics Biotechnologies GMBH's patents?

Inmatics Biotechnologies GMBH's patents average 19.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Inmatics Biotechnologies GMBH patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Inmatics Biotechnologies GMBH

USPTO PatentsView assignee record - 6 granted patents across 8 technology areas, recorded in grant years 2018–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Inmatics ranks #40,914 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 8 technology areas.

#40,914
of 49,997 US assignees by volume: 28th percentile
by Innovation Score (28.6/100): 19.8
avg claims per patent: -50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R40914 · Foreign Corporation #40,914 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 6 grants
LOWER-Q #40,914/49,997
PHOTO-FINISH Infacare Pharmaceuti…
CPC-NARROW C07K · 8 areas
INNOV-THIN 28.6/100
CLAIMS-RICH 19.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Infacare Pharmaceutical Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Inmatics’s 28.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (23%) Velocity 0.0 pts (0%) Breadth 10.0 pts (35%) Claim depth 11.9 pts (42%)

Qualcomm Incorporated · highest

85
Inmatics Biotechnolo… · this assignee

29
3D Lighting… · lowest

7

What this shows Inmatics's Innovation Score is 28.6/100 (28th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Inmatics?

Each dot is one of Inmatics’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Inmatics’s own 19.8 claims/patent is ABOVE the 14.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Inmatics vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Inmatics's grants concentrate

Inmatics Biotechnologies GMBH is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2019 (3 grants) versus a trough of 1 in 2018. By volume, Inmatics sits between Infacare Pharmaceutical Corporation and Innora GMBH.

Infacare Pharmace…

6
Infobank

6
Infor (US)

6
Ingell Holding B V

6
Inner-tite

6
Innerlite

6
Innomotive Soluti…

6
Innora

6
Inmatics Biotechn… ◀

6

What this shows Inmatics holds 6 patents at rank #40,863, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Inmatics

By rank, the assignees closest to #40,863 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Inmatics's primary technology class.

Inmatics's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 28th percentile higher than 28% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Inmatics Biotechnologies GMBH patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	16.7%
2019	3	50.0%
2020	2	33.3%

Which technologies does Inmatics Biotechnologies GMBH patent most?

C07K - Peptides 6

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 5

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 4

C12Y - Enzymes 2

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 2

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Inmatics Biotechnologies GMBH's patent record in context - here's where to go next.

Inmatics Biotechnologies GMBH's lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #40,914 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Inmatics Biotechnologies GMBH against Infacare Pharmaceutical Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 28.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.